PRINCETON, N.J.--(BUSINESS WIRE)--
Advaxis, Inc., (ADXS), a leader in developing the next generation of cancer immunotherapies, announced that ADXS-cHER2, its proprietary immunotherapy for the treatment of breast cancer and canine osteosarcoma, was featured on ABC News in an article titled “Bone Cancer Vaccine for Dogs Shows Promise for Breast Cancer”.
Advaxis sponsored a Phase 1 canine osteosarcoma study, conducted by Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine, evaluating the safety and efficacy of Advaxis’ proprietary immunotherapy, ADXS-cHER2, in companion dogs. The study has shown that the dogs that received the Advaxis immunotherapy are living significantly longer than the dogs whose owners elected not to participate in the study. Even with standard of care (SOC) treatment (affected limb amputation and follow-up chemotherapy) dogs have a median survival rate of only 1 year. Sasha, a 13 year old American Bulldog and the first dog treated in the study, has survived over 600 days.
“The proven ability of ADXS-cHER2 to extend the lives of companion dogs that have received Advaxis’ immunotherapy is a very exciting development not only for the owners who care so deeply about their pets, like Sasha, but for the potential of this drug product candidate in humans as well,” commented Daniel J. O’Connor, Chief Executive Officer of Advaxis. “Specifically, the encouraging preliminary data shown in these dogs provide strong rationale supporting the clinical development of ADXS-cHER2 to treat women with HER2+ breast cancer. We believe this is a potentially important value-creating opportunity for Advaxis to provide our immunotherapies to the veterinary market and to women facing the growing global issue of breast cancer. We are actively planning a clinical research program in the indication of HER2+ breast cancer in humans.”
ADXS-cHER2 is an Lm-LLO immunotherapy for HER2 overexpressing cancers (such as breast, gastric and other cancers in humans and for osteosarcoma in canines). ADXS-cHER2 secretes the cHER2 antigen, fused to LLO, directly inside APC that are capable of driving a cellular immune response to HER2 overexpressing cells. In preclinical analysis, localized effect is the inhibition of the Treg and MDSC cells that we believe may promote immunologic tolerance of the HER2 overexpressing cancer cells of the tumor.
About Canine Osteosarcoma
Osteosarcoma is the most common primary bone tumor in dogs, accounting for roughly 85% of tumors on the canine skeleton. Approximately 8,000-10,000 dogs a year (predominately middle to older-aged dogs and larger breeds) are diagnosed with osteosarcoma in the United States. This cancer initially presents as lameness and oftentimes visible swelling on the leg. Current standard of care treatment is amputation immediately after diagnosis, followed by chemotherapy and sometimes radiation for palliative care. Invariably, however, the cancer metastasizes to the lungs, eventually leading to death.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
ADXS-HPV is currently being evaluated in Phase 1 and 2 clinical trials for HPV-associated cancers: recurrent cervical cancer (completed Phase 2 study conducted in India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG U.S. study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the University of Pennsylvania, the Georgia Regents University Cancer Center, Brown University, Icahn School of Medicine at Mount Sinai, and others.
For more information please visit: www.advaxis.com
This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis’ proprietary immunotherapy, ADXS-cHER2, in companion dogs; the survival of dogs that receive the Advaxis immunotherapy; whether the preliminary data shown in canines provide strong rationale supporting the clinical development of ADXS-cHER2 to treat women with HER2+ breast cancer; the timing associated with clinical research in the indication of HER2+ breast cancer; whether ADXS-cHER2 may promote immunologic tolerance of the HER2 overexpressing cancer cells of tumors; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
- Health Care Industry
- breast cancer
Jenene Thomas, 908-938-1475
Investor Relations and Corporate Communications Advisor